84
Participants
Start Date
July 31, 2024
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2025
LYB005 low dose without adjuvant
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 middle dose without adjuvant
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 high dose without adjuvant
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 low dose with adjuvant
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 middle dose with adjuvant
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 high dose with adjuvant
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
Placebo
0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
Positive control
AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
Nucleus Network Pty Ltd., Melbourne
Yantai Patronus Biotech Co., Ltd.
INDUSTRY
Guangzhou Patronus Biotech Co., Ltd.
INDUSTRY